<?xml version='1.0' encoding='utf-8'?>
<document id="29204687"><sentence text="A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis." /><sentence text="Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors"><entity charOffset="11-22" id="DDI-PubMed.29204687.s2.e0" text="doxorubicin" /><entity charOffset="68-79" id="DDI-PubMed.29204687.s2.e1" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.29204687.s2.e0" e2="DDI-PubMed.29204687.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29204687.s2.e0" e2="DDI-PubMed.29204687.s2.e1" /></sentence><sentence text=" The aim of this study was to establish a physiologically based pharmacokinetic (PBPK) parent-metabolite model of zoptarelin doxorubicin and to apply it for drug-drug interaction (DDI) potential analysis"><entity charOffset="125-136" id="DDI-PubMed.29204687.s3.e0" text="doxorubicin" /></sentence><sentence text="" /><sentence text="The PBPK model was built in a two-step procedure" /><sentence text=" First, a model for doxorubicin was developed, using clinical data of a doxorubicin study arm"><entity charOffset="20-31" id="DDI-PubMed.29204687.s6.e0" text="doxorubicin" /><entity charOffset="72-83" id="DDI-PubMed.29204687.s6.e1" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.29204687.s6.e0" e2="DDI-PubMed.29204687.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29204687.s6.e0" e2="DDI-PubMed.29204687.s6.e1" /></sentence><sentence text=" Second, a parent-metabolite model for zoptarelin doxorubicin was built, using clinical data of three different zoptarelin doxorubicin studies with a dosing range of 10-267Â mg/m2, integrating the established doxorubicin model"><entity charOffset="39-61" id="DDI-PubMed.29204687.s7.e0" text="zoptarelin doxorubicin" /><entity charOffset="123-134" id="DDI-PubMed.29204687.s7.e1" text="doxorubicin" /><entity charOffset="208-219" id="DDI-PubMed.29204687.s7.e2" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.29204687.s7.e0" e2="DDI-PubMed.29204687.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29204687.s7.e0" e2="DDI-PubMed.29204687.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29204687.s7.e0" e2="DDI-PubMed.29204687.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29204687.s7.e1" e2="DDI-PubMed.29204687.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29204687.s7.e1" e2="DDI-PubMed.29204687.s7.e2" /></sentence><sentence text=" DDI parameters determined in vitro were implemented to predict the impact of zoptarelin doxorubicin on possible victim drugs"><entity charOffset="89-100" id="DDI-PubMed.29204687.s8.e0" text="doxorubicin" /></sentence><sentence text="" /><sentence text="In vitro, zoptarelin doxorubicin inhibits the drug transporters organic anion-transporting polypeptide 1B3 (OATP1B3) and organic cation transporter 2 (OCT2)"><entity charOffset="21-32" id="DDI-PubMed.29204687.s10.e0" text="doxorubicin" /></sentence><sentence text=" The model was applied to evaluate the in vivo inhibition of these transporters in a generic manner, predicting worst-case scenario decreases of 0" /><sentence text="5% for OATP1B3 and of 2" /><sentence text="5% for OCT2 transport rates" /><sentence text=" Specific DDI simulations using PBPK models of simvastatin (OATP1B3 substrate) and metformin (OCT2 substrate) predict no significant changes of the plasma concentrations of these two victim drugs during co-administration"><entity charOffset="47-58" id="DDI-PubMed.29204687.s14.e0" text="simvastatin" /><entity charOffset="60-67" id="DDI-PubMed.29204687.s14.e1" text="OATP1B3" /><entity charOffset="83-92" id="DDI-PubMed.29204687.s14.e2" text="metformin" /><pair ddi="false" e1="DDI-PubMed.29204687.s14.e0" e2="DDI-PubMed.29204687.s14.e0" /><pair ddi="false" e1="DDI-PubMed.29204687.s14.e0" e2="DDI-PubMed.29204687.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29204687.s14.e0" e2="DDI-PubMed.29204687.s14.e2" /><pair ddi="false" e1="DDI-PubMed.29204687.s14.e1" e2="DDI-PubMed.29204687.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29204687.s14.e1" e2="DDI-PubMed.29204687.s14.e2" /></sentence><sentence text="" /><sentence text="The first whole-body PBPK model of zoptarelin doxorubicin and its active metabolite doxorubicin has been successfully established"><entity charOffset="46-57" id="DDI-PubMed.29204687.s16.e0" text="doxorubicin" /><entity charOffset="84-95" id="DDI-PubMed.29204687.s16.e1" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.29204687.s16.e0" e2="DDI-PubMed.29204687.s16.e0" /><pair ddi="false" e1="DDI-PubMed.29204687.s16.e0" e2="DDI-PubMed.29204687.s16.e1" /></sentence><sentence text=" Zoptarelin doxorubicin shows no potential for DDIs via OATP1B3 and OCT2"><entity charOffset="12-23" id="DDI-PubMed.29204687.s17.e0" text="doxorubicin" /></sentence><sentence text="" /></document>